{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:46:48Z","timestamp":1785851208819,"version":"3.56.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study was conducted to determine the potential effect of other antimicrobial agents on the in vitro activity of gepotidacin against six WHO\n                      <jats:italic toggle=\"yes\">N. gonorrhoeae and<\/jats:italic>\n                      QC strain ATCC 49226 by checkerboard assays using Graver-Wade broth. Synergy and antagonism were evaluated using fractional inhibitory concentration (FIC) and FIC index (FICI) results for gepotidacin and comparator agents (azithromycin, cefixime, ceftriaxone, gemifloxacin, sitafloxacin, gentamicin, spectinomycin, doxycycline, and lefamulin). The evaluation of FICI showed no antagonistic or synergistic interactions, while the evaluation of individual FIC values revealed strain- and agent-specific synergistic or additive effects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00059-26","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:48:45Z","timestamp":1783007325000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    antibacterial activity of gepotidacin in combination with other antimicrobial agents against\n                    <i>Neisseria gonorrhoeae<\/i>\n                    isolates"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2885-6129","authenticated-orcid":true,"given":"Laura M.","family":"Koeth","sequence":"first","affiliation":[{"name":"Laboratory Specialists, Inc.","place":["Westlake, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"DiFranco-Franco","sequence":"additional","affiliation":[{"name":"Laboratory Specialists, Inc.","place":["Westlake, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"West","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Unit, GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":true,"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Unit, GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02047-16"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky162"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-22"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02196-7"},{"key":"e_1_3_2_8_2","unstructured":"GSK. 2025. Blujepa (gepotidacin) [package insert]. U.S. Food and Drug Administration website. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218230s001lbl.pdf"},{"key":"e_1_3_2_9_2","unstructured":"Medicines & Healthcare products Regulatory Agency. 2025. Press release: MHRA approves UK\u2019s first new type of antibiotic for urinary tract infections in nearly 30 years. Available from: https:\/\/www.gov.uk\/government\/news\/mhra-approves-uks-first-new-type-of-antibiotic-for-urinary-tract-infections-in-nearly-30-years"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00628-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101318"},{"key":"e_1_3_2_12_2","unstructured":"Centers for Disease Control and Prevention. 2026. Gonococcal isolate surveillance project (GISP). CDC. Available from: https:\/\/www.cdc.gov\/sti-statistics\/gisp-profiles\/index.html. Retrieved 10 Apr 2026."},{"key":"e_1_3_2_13_2","unstructured":"World Health Organization. 2024. Global gonococcal antimicrobial surveillance programme (GASP). WHO. Available from: https:\/\/www.who.int\/initiatives\/gonococcal-antimicrobial-surveillance-programme. Retrieved 10 Apr 2026."},{"key":"e_1_3_2_14_2","volume-title":"CLSI document M07-A11","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In CLSI document M07-A11, 11th ed. Wayne, PA.","edition":"11"},{"key":"e_1_3_2_15_2","volume-title":"M100-S30","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing. In M100-S30, 30th ed. Clinical Laboratory and Standards Institute, Wayne, PA.","edition":"30"},{"key":"e_1_3_2_16_2","first-page":"5","volume-title":"Clinical microbiology procedures handbook","author":"Humphries RM","year":"2016","unstructured":"Humphries RM. 2016. 5.16 Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p 5. In Clinical microbiology procedures handbook, 4th ed. ASM Press, Washington, DC.","edition":"4"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2007.00776.x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-016-0838-9"},{"key":"e_1_3_2_19_2","first-page":"365","volume-title":"Antibiotics in laboratory medicine","author":"Pillai SK","year":"2005","unstructured":"Pillai SK, Moellering RC, Eliopoulos GM. 2005. Antimicrobial combinations, p 365\u2013440. In Lorian V (ed), Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, New York."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae233"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw288"},{"key":"e_1_3_2_22_2","volume-title":"M100-S32","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. In M100-S32, 32nd ed. Clinical Laboratory and Standards Institute, Wayne, PA.","edition":"32"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00348-23"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193678"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt540"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00059-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00059-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:02:32Z","timestamp":1785848552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00059-26"}},"subtitle":[],"editor":[{"given":"Boudewijn L.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,5]]}},"alternative-id":["10.1128\/aac.00059-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00059-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"2026-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00059-26"}}